All News
EGPA Review
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Read Article
Toll-Like Receptor Drugs Effective in Cutaneous Lupus
MedPage Today
Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.
Read Article
Vitamin D in Rheumatic Disease - is it Good Enough?
Vitamin D deficiency or insufficiency of is highly prevalent and has been often associated with inflammatory rheumatic diseases, raising the question of whether inadequate vitamin D status contributes to immune dysregulation, incipient disease, increased disease activity, or poor skeletal outco
Read Article
Breaking the Rules: Dual-Advanced Combinations in Rheumatology
For decades, the standard of care in rheumatology has been combination therapy - pairing methotrexate (MTX) with an advanced biologic or synthetic agent to achieve optimal outcomes.
Read Article
Great Lectures; Great Presentations
Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.
Read Article
Follow the Money (4.23.2026)
Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.
Read Article
Weight-loss drugs may affect joints directly
EulrekAlert!
A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis.
Toll-Like Receptor Drugs Effective in Cutaneous Lupus
Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.
https://t.co/R1wbJHXwjD https://t.co/65HtG0Te94
Dr. John Cush RheumNow ( View Tweet)
Branebrutinib (Bruton's tyrosine kinase inhibitor) was studied in phase 2 RCT of 85 RA pts for 12 weeks and was safe but failed to achieve an ACR50 response (19% BTK vs 33% PBO; p=0·16). https://t.co/gTjLJm9iIW https://t.co/GN9p1P8ZNJ
Dr. John Cush RheumNow ( View Tweet)
UCB has aquired Candid Therapeutics for $2 billion; plan to lead in autoimmune dz by acquiring cizutamig - a T cell engager. Its been studied in >100 pts, including early Global Phase 2 RCTs of myasthenia gravis & ILD. https://t.co/xz4uEhvxu6 https://t.co/6FS1riLecW
Dr. John Cush RheumNow ( View Tweet)
FDA has published final guidance on Postapproval Pregnancy Safety Studies; how to study outcomes in pregnant women exposed to drugs & biologics- updates on registries,statistical methods, complementary studies, rare Rx exposures https://t.co/NWxrgB0dPQ https://t.co/ckyaJ07MQ0
Dr. John Cush RheumNow ( View Tweet)
Full read review of Preclinical Rheumatoid Arthritis:
- Mucosal Origin Hypothesis
- Gut Microbiota
- Smoking & environment
- Periodontitis
- Immunosenescence
- T cell abnormalities
- Drug prevention https://t.co/SdcDtYGObO https://t.co/2UYGs5eTsu
Dr. John Cush RheumNow ( View Tweet)
EMA/European Commission has aproved Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults https://t.co/Fv9DON1AvB https://t.co/Li79tKzMxK
Dr. John Cush RheumNow ( View Tweet)
DERM on RheumNow PODCAST (April 2026)
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy and side https://t.co/SlCGA364gj
Dr. John Cush RheumNow ( View Tweet)
Anifrolumab (Saphnelo) approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus based on SC-TULIP study. Presumeably, all prior CRL issues resolved to FDA satisfaction... https://t.co/ZtZmJLcGYa https://t.co/4B2YDpFaep
Dr. John Cush RheumNow ( View Tweet)
APR: Methotrexate
Companion slide deck for the Advanced Practice Rheum: Methotrexate video, featuring Dr. Jack Cush.
https://t.co/8422FKN4dq https://t.co/6gVS7dA8Gi
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has accepted Genetech application for obinutuzumab (Gazyva) to treat SLE (currently only approved for lupus nephritis) - based on Phase III ALLEGORY study w/ Gazyva showing signif reduced dz activity https://t.co/louTYyN6bN https://t.co/Hy1gGliamn
Dr. John Cush RheumNow ( View Tweet)
TriNetX study of 7,929 RA pts Rx w/ bDMARDs (n 2668) w/in 6 mos of elective hand surgery - perioperative bDMARD continuation (34%) was not associated with significant increases in risks of wound healing failures (1.4% vs 1.4%) or SSI (2% vs 1.5%) https://t.co/NY6l2jRswb https://t.co/IxoYtLNGvf
Links:
Dr. John Cush RheumNow ( View Tweet)
Weight-loss drugs may affect joints directly
A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis. https://t.co/xKm8Ng7fXO
Dr. John Cush RheumNow ( View Tweet)
Malignancies Not Increased with Biologic Therapies
The risk of malignancy in RA patients receiving biologic agents was evaluated by metanalysis of RCTs and found no significant increased risk of malignancy compared with other DMARDs or with placebo.
https://t.co/ZEO4jP5RwA https://t.co/C1YeTSh7ZN
Dr. John Cush RheumNow ( View Tweet)
